Investor profile
Monograph Capital
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Monograph Capital finds and funds innovative life sciences companies, aiming to help translate promising science into potential, life-changing treatments for patients around the world. The firm focuses on therapeutics, diagnostics, and digitally-enabled healthcare, and partners with the most innovative young companies and entrepreneurs to support breakthrough science across North America, the United Kingdom, and Europe. Monograph is a transatlantic team combining differentiated sourcing, long-standing relationships with pharma, deep medical expertise, and seasoned operating experience. The team — comprising M.D.s and Ph.D.s with over 55 years of cumulative healthcare investing experience — acts as both investor and company-builder, co-founding companies alongside scientists and taking active operational and board roles to help portfolio companies scale and improve health outcomes for patients.
Notable quotes
“The pace, focus, and quality of execution have been exceptional. This milestone reflects not only the strength of the science, but what's possible when the right team moves with urgency around a clear vision for patients.”
“We combine differentiated sourcing, long-standing relationships with pharma, deep medical expertise, and seasoned operating experience to help create value for our company partners and investors, with a goal of improving health outcomes for patients over time.”
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Human Immunology Biosciences (HI-Bio) | Series A | — | 2021-08 |
| AviadoBio | Series A | — | 2021-11 |
| Ascend Advanced Therapies | Founding | — | 2021-12 |
| RegASK | Series A | — | 2022-12 |
| ODAIA | Series B | — | 2023-04 |
| Nocion Therapeutics | Series B | — | 2024-02 |
| Autobahn Therapeutics | Series C | — | 2024-07 |
| Ouro Medicines | Series A | — | 2024-12 |
| Maxion Therapeutics | Series A | — | 2025-02 |
| RQ Biotechnology | Series A | — | 2026-06 |
Frequent co-investors
Fit check
Is Monograph Capital a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit